scispace - formally typeset
G

Guido Kroemer

Researcher at Institut Gustave Roussy

Publications -  1546
Citations -  294816

Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.

Papers
More filters
Journal ArticleDOI

Mitochondrial Release of Caspase-2 and -9 during the Apoptotic Process

TL;DR: The data suggest that caspase-2 and -9 zymogens are essentially localized in mitochondria and that the disruption of the outer mitochondrial membrane occurring early during apoptosis may be critical for their subcellular redistribution and activation.
Journal ArticleDOI

Mitochondrial metabolism and cancer.

TL;DR: The cancer cell-intrinsic and cell-extrinsics mechanisms through which mitochondria influence all steps of oncogenesis are reviewed, with a focus on the therapeutic potential of targeting mitochondrial metabolism for cancer therapy.

Autophagy-Inflammation-Cell Death Axis in Organismal Aging

TL;DR: A combination of mitochondrial dysfunction and insufficient autophagy may contribute to multiple aging-associated pathologies.
Journal ArticleDOI

Cardioprotection and lifespan extension by the natural polyamine spermidine

Tobias Eisenberg, +69 more
- 01 Dec 2016 - 
TL;DR: It is shown that oral supplementation of the natural polyamine spermidine extends the lifespan of mice and exerts cardioprotective effects, reducing cardiac hypertrophy and preserving diastolic function in old mice, and suggests a new and feasible strategy for protection against cardiovascular disease.
Journal ArticleDOI

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

TL;DR: The capacity of both conventional and targeted anticancer therapies to enhance the immunogenic properties of malignant cells and to stimulate immune effector cells, either directly or by subverting the immunosuppressive circuitries that preclude antitumor immune responses in cancer patients are discussed.